Heme/Onc

Clinical Questions: How do you dose argatroban?

April 16, 2009
Clinical Questions: How do you dose argatroban?

Frederick Gandolfo, MD

Case: An 85 year-old woman admitted to the hospital with pneumonia and after a prolonged hospital course developed heparin-induced thrombocytopenia (HIT). She is currently being treated with argatroban and her platelet counts are recovering. You are the covering physician and are called by the lab for an INR of 12 on her routine labs. The patient shows no signs of bleeding and she is not on warfarin. The PTT at the time…

Read more »

Prostate Cancer and Antioxidants

February 25, 2009

Commentary by Christopher Tully MD, PGY-1

Faculty Peer Reviewed

An apple a day. . . keeps the prostate cancer away? While it is an overstatement to say that an apple can prevent cancer, the notion of taking “something” to prevent cancer initiation and growth is nothing new. Primary prevention has long been a goal of researchers and physicians with the aim of preventing the morbidity and mortality associated with malignant disease. Prostate cancer is an appropriate choice in studying this topic since we…

Read more »

Tackling Cancer Control Worldwide: Report From the 2008 World Cancer Congress

December 11, 2008
Tackling Cancer Control Worldwide: Report From the 2008 World Cancer Congress

Commentary by Antonella Surbone MD PhD FACP, NYU Department of Medicine and Clinical Correlations Ethics Section Editor

On Tuesday December 9th 2008, leading global cancer organizations met in Atlanta to discuss the 2008 WHO World Cancer Report predicting that cancer will overtake heart disease as the world’s top killer by 2010, and that global cancer cases and deaths will more than double by 2030. They called on governments to act, by ratifying an international tobacco control treaty and by asking the US to…

Read more »

Class Act: Soy and Breast Cancer – What’s the Connection?

November 26, 2008
Class Act: Soy and Breast Cancer – What’s the Connection?

Commentary by Alexis Melnick, NYU School of Medcine Class of 2009

Faculty peer reviewed

With the increasing popularity of soy foods in the American diet, there has been considerable debate over the link between soy and the risk of cancer, particularly cancer of the breast. The interest in this association stems from soy-containing isoflavones, soybean-derived compounds with chemical structures similar to estrogens that act as weak partial agonists at estrogen receptors. Initial data supported the chemopreventive potential of soy and were based on several findings: the…

Read more »

Grand Rounds: “Advances in the Therapy of HER2 Positive Breast Cancer

November 19, 2008
Grand Rounds: “Advances in the Therapy of HER2 Positive Breast Cancer

Commentary by Jon-Emile Kenny MD, PGY- 2

 

Please also see the clinical vignette presented before last week’s grand rounds.

Medical grand rounds on November 12, 2008 was given by Dr. Jose Baselga, MD.  His lecture, ‘Advances in the Therapy of HER2 Positive Breast Cancer’ highlighted the biochemical aspects of HER receptors and the current and future pharmacological implications thereof.

Roughly one in four breast cancers are HER2 receptor positive.  Phenotypically, these cancers tend to present as locally advanced tumours at an…

Read more »

Grand Rounds: “A New Mechanism of Platelet Thrombus Regulation Induced by ADAMTS-18: Clinical Implications”

November 6, 2008
Grand Rounds: “A New Mechanism of Platelet Thrombus Regulation Induced by ADAMTS-18: Clinical Implications”

Commentary by Yelena Kopyltsova MD, PGY-2

Please also see the clinical vignette presented before last week’s grand rounds.

Last week’s grand rounds speaker was Simon Karpatkin MD, NYU Professor of Medicine & Director of the NYU Division of Hematology. In the 80s, multiple cases of autoimmune thrombocytopenic purpura were observed in patients with AIDS.  It was noted that these patients had elevated anti-platelet IgG levels (extracted from immune complexes), which correlated strongly with low platelets.  Dr. Karpatkin and his colleagues became interested in elucidating the mechanism…

Read more »

Grand Rounds: “Molecular Genetics of Colorectal Cancer”

October 19, 2008
Grand Rounds: “Molecular Genetics of Colorectal Cancer”

Commentary by Sabina Berezovskaya MD PGY-3

Please also see the clinical vignette presented during last week’s grand rounds

On Wednesday, October 8, 2004, the NYU Department of Medicine Grand Rounds featured guest lecturer Vincent Yang, M.D. Ph.D., Professor of Medicine and Director of  Division of Digestive Diseases at Emory University School Medicine with a presentation entitled  “Molecular Genetics of Colorectal Cancer”.

 

Dr. Yang first oriented the audience to the outline of the talk and began his presentation with a case…

Read more »

Breaking News: USPSTF Recommends Against Routine Screening for Colorectal Cancer After Age 75

October 8, 2008

Commentary by Andrew McKinstry MD, PGY-1 (reviewed by Michael Poles, MD, Associate Editor Clinical Correlations, Assistant Professor of Medicine, Section of Gastroenterology)

Hot on the heels of its recommendation in August against routine screening for prostate cancer in men over 75, the US Preventive Services Task Force has issued recommendations against routine screening for colorectal cancer in patients over the age of 75- Yes, you read that correctly, NO routine screening for colorectal cancer past age 75.  In a report updating their recommendations from 2002, the…

Read more »

Grand Rounds: Clinical Development of Anti-Cancer Drugs: Succeed Slowly or Fail Fast

October 3, 2008
Grand Rounds: Clinical Development of Anti-Cancer Drugs: Succeed Slowly or Fail Fast

Commentary by Daniel Egan MD, PGY2

Please also see the clinical vignette presented during last week’sgrand rounds

On Wednesday, September 24, 2008, the NYU Department of Medicine Grand Rounds featured guest speaker Hilary Calvert, MD, Professor of Medical Oncology at the University of Newcastle upon Tyne, England, with a lecture entitled “Clinical Development of Anti-Cancer Drugs: Succeed Slowly or Fail Fast.”

Dr. Calvert first oriented the audience by reviewing the traditional method in which new chemotherapeutic drugs have been developed and introduced to the…

Read more »

Class Act: The Use of MRI in Breast Cancer Screening

August 28, 2008
Class Act: The Use of MRI in Breast Cancer Screening

Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. Prior to publication, each commentary is thoroughly reviewed for content by a faculty member.

Commentary by Daniel Green MSIV and Boris Kobrinsky MD, Assistant Professor, NYU Division of Oncology

In 2008, an estimated 182,460 women in the United States will be diagnosed with invasive breast cancer, and 40,480 women will die of the disease as it remains the demographic’s second leading cause of cancer mortality.(1) Fortunately, breast cancer…

Read more »

Breaking News: USPSTF Issues New Prostate Cancer Screening Guidelines

August 5, 2008

Commentary by Cara Litvin MD, Executive Editor, Clinical Correlations

The US Preventive Services Task Force issued new guidelines for prostate cancer screening on Monday.  For the first time, the task force recommends AGAINST routine screening in patients over 75 years of age, citing the “moderate to substantial” harms over small to no benefits from screening. The task force reports that there continues to be inadequate evidence that the PSA improves healthcare outcomes at any age.  However, even if there is eventual evidence that screening is beneficial in younger patients, because men over…

Read more »

Neutropenic Precautions Demystified

June 13, 2008
Neutropenic Precautions Demystified

Commentary by Rachana Jani MD, PGY-1 and Neal Steigbigel MD, Professor of Medicine (Infectious Diseases/Immunology)

Rachana Jani MD:  Walking onto an oncology floor, one cannot help but notice the precautionary signs that segregate these patients from the rest of the hospital. “No fresh fruits or flowers.” “Neutropenic isolation, please see nurse before entering.” The idea of neutropenic precautions first emerged in the 1960s when myelosuppressive therapy came to the forefront of cancer treatment. It only made sense that patients with an impaired immune…

Read more »